BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 24,369 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 24,369 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total transaction of $7,380,639.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

John Oyler also recently made the following trade(s):

• On Monday, December 15th, John Oyler sold 75,631 shares of BeOne Medicines stock. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49.

BeOne Medicines Stock Performance

NASDAQ ONC traded up $1.74 during trading on Wednesday, reaching $306.05. The company’s stock had a trading volume of 245,211 shares, compared to its average volume of 383,520. The firm has a 50 day moving average price of $329.62 and a 200 day moving average price of $306.92. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $385.22. The firm has a market capitalization of $36.28 billion, a price-to-earnings ratio of 600.10 and a beta of 0.45. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03.

Analysts Set New Price Targets

Several brokerages recently issued reports on ONC. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Morgan Stanley lifted their price objective on BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Citizens Jmp increased their target price on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Citigroup raised their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $365.79.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of ONC. Sequoia Financial Advisors LLC boosted its stake in BeOne Medicines by 4.1% in the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after buying an additional 50 shares in the last quarter. Penserra Capital Management LLC raised its stake in BeOne Medicines by 2.7% during the third quarter. Penserra Capital Management LLC now owns 2,981 shares of the company’s stock worth $1,015,000 after acquiring an additional 79 shares in the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of BeOne Medicines by 3.0% in the third quarter. Allianz Asset Management GmbH now owns 3,400 shares of the company’s stock worth $1,158,000 after acquiring an additional 100 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of BeOne Medicines by 11.7% in the 3rd quarter. Blue Trust Inc. now owns 967 shares of the company’s stock valued at $329,000 after purchasing an additional 101 shares in the last quarter. Finally, Anchor Investment Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at approximately $26,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.